Intervention with vitamins in patients with nonproliferative diabetic retinopathy: A pilot study

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 1451-1458

  Smolek, Michael K ^a   Notaroberto, Neil F ^a,b   Jaramillo, Arley G ^a,b   Pradillo, Lisa R ^a,b  

^a CLEVER Eye Institute   (United States)

^b EyeCare 20/20 ^*  (United States)

Author keywords

Diabetes; Diabetic retinopathy; Homocysteine; Microperimetry; Nitric oxide; Vitamin B

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; METANX; PYRIDOXINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; DIABETIC RETINOPATHY; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONPROLIFERATIVE DIABETIC RETINOPATHY; OPEN STUDY; PERIMETRY; PILOT STUDY; PROSPECTIVE STUDY; RETINA MACULA EDEMA; RETINAL SENSITIVITY THRESHOLD; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL SYSTEM PARAMETERS;

EID: 84880300341     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S46718     Document Type: Article

References (36)

1. Fong DS, Aiello LP, Ferris FL, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27:2540-2553.
2. American Academy of Ophthalmology Retina/Vitreous Panel, Preferred Practice Patterns Committee. Diabetic retinopathy. San Francisco, CA: American Academy of Ophthalmology. Available from: http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=d0c853d3-219f-487b-a524-326ab3cecd9a. Accessed May 31, 2013.
3. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88: 1254-1264.
4. Perla-Kaján J, Twardowski T, Jakubowski H. Mechanisms of homocysteine toxicity in humans. Amino Acids. 2007;32:561-572.
5. Stanger O, Wonisch W. Enzymatic and non-enzymatic antioxidative effects of folic acid and its reduced derivates. Subcell Biochem. 2012;56:131-161.
6. Hoffman M. Hypothesis: hyperhomocysteinemia is an indicator of oxidant stress. Med Hypotheses. 2011;77:1088-1093.
7. Stanger O, Herrmann W, Pietrzik K, et al. DACH-LIGA homocysteine (German, Austrian and Swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med. 2003;41:1392-1403.
8. Looker HC, Fagot-Campagna A, Gunter EW, et al. Homocysteine and vitamin B(12) concentrations and mortality rates in type 2 diabetes. Diabetes Metab Res Rev. 2007;23:193-201.
9. Ebesunun MO, Obajobi EO. Elevated plasma homocysteine in type 2 diabetes mellitus: a risk factor for cardiovascular diseases. Pan Afr Med J. 2012;12:48.
10. Sudchada P, Saokaew S, Sridetch S, Incampa S, Jaiyen S, Khaithong W. Effect of folic acid supplementation on plasma total homocysteine levels and glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2012;98:151-158.
11. Leishear K, Boudreau RM, Studenski SA, et al. Relationship between vitamin B12 and sensory and motor peripheral nerve function in older adults. J Am Geriatr Soc. 2012;60:1057-1063.
12. González R, Pedro T, Martinez-Hervas S, et al. Plasma homocysteine levels are independently associated with the severity of peripheral polyneuropathy in type 2 diabetic subjects. J Peripher Nerv Syst. 2012;17:191-196.
13. Bagheri M, Jahromi BM, Zamani A. Folic acid may be a potential addition to diabetic foot ulcer treatment - a hypothesis. Int Wound J. 2011;8:658-660.
14. Jacobs AM, Cheng D. Management of diabetic small-fiber neuropathy with combination L-methylfolate, methylcobalamin, and pyridoxal 5′-phosphate. Rev Neurol Dis. 2011;8:39-47.
15. Miranda-Massari JR, Gonzalez MJ, Jimenez FJ, Allende-Vigo MZ, Duconge J. Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control. Curr Clin Pharmacol. 2011;6:260-273.
16. Leishear K, Ferrucci L, Lauretani F, et al. Vitamin B12 and homocysteine levels and 6-year change in peripheral nerve function and neurological signs. J Gerontol A Biol Sci Med Sci. 2012;67:537-543.
17. Fonseca VA, Lavery LA, Thethi TK, et al. Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. Am J Med. 2013;126:141-149.
18. Vaccaro O, Ingrosso D, Rivellese A, Greco G, Riccardi G. Moderate hyperhomocysteinaemia and retinopathy in insulin-dependent diabetes. Lancet. 1997;349:1102-1103.
19. Hoogeveen EK, Kostense PJ, Eysink PE, et al. Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: the Hoorn study. Arch Intern Med. 2000;160:2984-2990.
20. Huang EJ, Kuo WW, Chen YJ, et al. Homocysteine and other biochemical parameters in type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. Clin Chim Acta. 2006;366:293-298.
21. Cho HC. The relationship among homocysteine, bilirubin, and diabetic retinopathy. Diabetes Metab J. 2011;35:595-601.
22. Goldstein M, Leibovitch I, Yeffimov I, Gavendo S, Sela BA, Loewenstein A. Hyperhomocysteinemia in patients with diabetes mellitus with and without diabetic retinopathy. Eye (Lond). 2004;18:460-465.
23. Coral K, Angayarkanni N, Gomathy N, Bharathselvi M, Pukhraj R, Rupak R. Homocysteine levels in the vitreous of proliferative diabetic retinopathy and rhegmatogenous retinal detachment: its modulating role on lysyl oxidase. Invest Ophthalmol Vis Sci. 2009;50:3607-3612.
24. Satyanarayana A, Balakrishna N, Pitla S, et al. Status of B-vitamins and homocysteine in diabetic retinopathy: association with vitamin-B12 deficiency and hyperhomocysteinemia. PLoS One. 2011;6:e26747.
25. Lim CP, Loo AV, Khaw KW, et al. Plasma, aqueous and vitreous homocysteine levels in proliferative diabetic retinopathy. Br J Ophthalmol. 2012;96:704-707.
26. Wright AD, Martin N, Dodson PM. Homocysteine, folates, and the eye. Eye (Lond). 2008;22:989-993.
27. Chang HH, Lin DP, Chen YS, et al. Intravitreal homocysteinethiolactone injection leads to the degeneration of multiple retinal cells, including photoreceptors. Mol Vis. 2011;17:1946-1956.
28. Christen WG, Glynn RJ, Chew EY, Albert CM, Manson JE. Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med. 2009;169:335-341.
29. Gopinath B, Flood VM, Rochtchina E, Wang JJ, Mitchell P. Homocysteine, folate, vitamin B-12, and 10-y incidence of age-related macular degeneration. Am J Clin Nutr. May 1, 2013. [Epub ahead of print.]
30. Narayanasamy A, Subramaniam B, Karunakaran C, et al. Hyperhomocysteinemia and low methionine stress are risk factors for central retinal venous occlusion in an Indian population. Invest Ophthalmol Vis Sci. 2007;48:1441-1446.
31. Stanger O, Weger M, Obeid R, et al. Impairment of homocysteine metabolism in patients with retinal vascular occlusion and non-arteritic ischemic optic neuropathy. Clin Chem Lab Med. 2005;43: 1020-1025.
32. Stanger O, Weger M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med. 2003;41:1444-1454.
33. Tousoulis D, Kampoli AM, Stefanadis C. Diabetes mellitus and vascular endothelial dysfunction: current perspectives. Curr Vasc Pharmacol. 2012;10:19-32.
34. Omae T, Nagaoka T, Tanano I, Yoshida A. Homocysteine inhibition of endothelium-dependent nitric oxide-mediated dilation of porcine retinal arterioles via enhanced superoxide production. Invest Ophthalmol Vis Sci. 2013;54:2288-2295.
35. Savchenko A, Barnes S, Kramer RH. Cyclic-nucleotide-gated channels mediate synaptic feedback by nitric oxide. Nature. 1997;390: 694-698.
36. Fan Q, Teo YY, Saw SM. Applications of advanced statistics in ophthalmology. Invest Ophthalmol Vis Sci. 2011;52:6059-6065